Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug58 | 50 mg/mL Virazole Wiki | 0.71 |
drug25 | 100 mg/mL Virazole Wiki | 0.71 |
drug794 | Clopidogrel 75mg Wiki | 0.50 |
Name (Synonyms) | Correlation | |
---|---|---|
drug2881 | Rivaroxaban 2.5 MG Wiki | 0.50 |
drug291 | Aspirin 75mg Wiki | 0.50 |
drug3333 | Tele-medicine platform Wiki | 0.50 |
drug24 | 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse Wiki | 0.50 |
drug30 | 1: Prone positioning Wiki | 0.50 |
drug316 | Atorvastatin 40mg Wiki | 0.50 |
drug42 | 2: No instruction regarding positioning Wiki | 0.50 |
drug2309 | Omeprazole 20mg Wiki | 0.50 |
drug991 | Data collection Wiki | 0.22 |
Name (Synonyms) | Correlation | |
---|---|---|
D000787 | Angina Pectoris NIH | 0.50 |
D054143 | Heart Failure, Systolic NIH | 0.50 |
D009203 | Myocardial Ischemia NIH | 0.29 |
Name (Synonyms) | Correlation | |
---|---|---|
D003327 | Coronary Disease NIH | 0.25 |
D003324 | Coronary Artery Disease NIH | 0.25 |
D009205 | Myocarditis NIH | 0.18 |
D054556 | Venous Thromboembolism NIH | 0.17 |
D006333 | Heart Failure NIH | 0.17 |
D020246 | Venous Thrombosis NIH | 0.15 |
D011655 | Pulmonary Embolism NIH | 0.13 |
D004617 | Embolism NIH | 0.13 |
D013923 | Thromboembolism NIH | 0.11 |
D013927 | Thrombosis NIH | 0.09 |
D002318 | Cardiovascular Diseases NIH | 0.08 |
D013577 | Syndrome NIH | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001681 | Angina pectoris HPO | 0.50 |
HP:0001658 | Myocardial infarction HPO | 0.29 |
HP:0001677 | Coronary artery atherosclerosis HPO | 0.25 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001635 | Congestive heart failure HPO | 0.18 |
HP:0012819 | Myocarditis HPO | 0.18 |
HP:0002625 | Deep venous thrombosis HPO | 0.15 |
HP:0002204 | Pulmonary embolism HPO | 0.13 |
HP:0001907 | Thromboembolism HPO | 0.10 |
HP:0001626 | Abnormality of the cardiovascular system HPO | 0.08 |
Navigate: Correlations HPO
There are 4 clinical trials
Management of known patients with cardiovascular disease (in particular the whole spectrum of atherosclerotic ischaemic coronary artery disease, essential hypertension under treatment, and also patients with chronic heart failure under medication) and with other associated chronic pathologies, with obvious effects on the management of the pandemic with modern / distance means (e-Health) of patients at high risk of mortality in contact with coronavirus. Given the Covid-19 Pandemic, all the above complex cardiovascular patients are under the obligation to stay in the house isolated and can no longer come to standard clinical and paraclinical monitoring and control visits. Therefore, a remote management solution (tele-medicine) of these patients must be found. The Investigators endeavour is to create an electronic platform to communicate with these patients and offer solutions for their cardiovascular health issues (including psychological and religious problems due to isolation). The Investigators intend to create this platform for communicating with a patient and stratify their complaints in risk levels. A given specialist will sort and classify their needs on a scale, based on specific algorithms (derived from the clinical European Cardiovascular Guidelines), and generate specific protocols varying from 911 like emergencies to cardiological advices or psychological sessions. These could include medication changing of doses, dietary advices or exercise restrictions. Moreover, in those patients suspected of COVID infection, special assistance should be provided per protocol.
Description: Development of an electronic (e-HEALTH) framework structure for management of patients with known cardiovascular disease in COVID19 pandemic social context
Measure: Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients Time: 6 monthsDescription: patients come into direct contact with the case coordinator, who provides ongoing assistance, including for connecting to devices that ensure real-time data transmission and directing to specialist teams that establish stage diagnosis and management / therapy behavior (including adjustment). doses, decisions to discontinue medication or to add medication);
Measure: Number of patients included in this platform Time: 6 monthsDescription: Will be the number of sessions per patient multiplied with the number of patients included
Measure: Number of consultations/sessions given Time: 6 monthsThe outbreak of a novel coronavirus (SARS-CoV-2) and associated COVID-19 disease in late December 2019 has led to a global pandemic. At the time of writing, there have been 150 000 confirmed cases and 3500 deaths. Apart from the morbidity and mortality directly related to COVID-19 cases, society has had to also cope with complex political and economic repercussions of this disease. At present, and despite pressing need for therapeutic intervention, management of patients with COVID-19 is entirely supportive. Despite the majority of patients experiencing a mild respiratory illness a subgroup, and in particular those with pre-existing cardiovascular disease, will experience severe illness that requires invasive cardiorespiratory support in the intensive care unit. Furthermore, the severity of COVID-19 disease (as well as the likelihood of progressing to severe disease) appears to be in part driven by direct injury to the cardiovascular system. Analysis of data from two recent studies confirms a significantly higher likelihood of acute cardiac injury in patients who have to be admitted to intensive care for the management of COVID-19 disease. The exact type of acute of cardiac injury that COVID-19 patients suffer remains unclear. There is however mounting evidence that heart attack like events are responsible. Tests ordinarily performed to definitely assess for heart attacks will not be possible in very sick COVID-19 patients. Randomising patients to cardioprotective medicines will help us understand the role of the cardiovascular system in COVID-19 disease. It will also help us determine if there is more we can do to treat these patients.
Description: All-cause mortality
Measure: All-cause mortality at 30 days after admission Time: at 30 days after admissionDescription: Absolute change in serum troponin from admission (or from suspicion/diagnosis of Covid-19 if already an inpatient) measurement to peak value (measured using high sensitivity troponin assay). (Phase I interim analysis)
Measure: Absolute change in serum troponin from admission to peak value Time: within 7 days and within 30 days of admissionDescription: Discharge Rate: Proportion of patients discharged (or documented as medically fit for discharge)
Measure: Discharge Rate Time: at 7 days and 30 days after admissionDescription: Intubation Rate: Proportion of patients who have been intubated for mechanical ventilation
Measure: Intubation Rate Time: at 7 days and at 30 days after admissionPatients with COVID-19 in the Intensive Care Unit (ICU) or hospitalized with severe form have a poor prognosis (almost 30% rate of death). They present often a high cardiovascular risk profile (almost 30% of hypertension and 19% of diabetes). Troponin has been described to be elevated in a high proportion of patients (one fifth of all patients and 50% of non-survivors) suggesting the possibility of cardiomyopathies. High levels of DDimers (81% of non survivors) and fibrin degradation products are also associated with increased risk of mortality suggesting also the possibility of venous thromboembolism. Therefore, screening for cardiomyopathies and venous thromboembolism could represent an important challenge for patients with COVID-19 management.
Description: Incidence of cardiomyopathies and/or venous thromboembolism at day 28
Measure: Determine the incidence of cardiomyopathies and venous thromboembolism Time: 28 daysDescription: Incidence of mortality at day 28
Measure: Mortality Time: 28 daysDescription: Number of day of using mechanical ventilation for each patients
Measure: Duration of mechanical ventilation Time: hospitalisation durationDescription: Incidence of shock during hospitalisation
Measure: Shock Time: hospitalisation durationDescription: Number of day at hospital
Measure: length of stay Time: hospitalisation durationDescription: Setting up or not of mechanical ventilation
Measure: Mechanical ventilation Time: hospitalisation durationDescription: Administration or not of renal replacement therapy
Measure: Renal replacement therapy Time: hospitalisation durationThis registry will evaluate the impact of the COVID19 outbreak on Cardiac patients admitted in the Intensive Care Unit of the Pitie-Salpetriere Hospital in Paris, France
Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports